Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
Information source: Allergan
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Ocular Hypertension
Intervention: brimonidine/timolol fixed combination (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Allergan
Summary
The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed
Combination in patients with glaucoma or ocular hypertension
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment
Primary outcome: IOP
Eligibility
Minimum age: 21 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Clinical diagnosis of glaucoma or ocular hypertension in both eyes
- Patient requires IOP-lowering in both eyes
Exclusion Criteria:
- Uncontrolled medical conditions
- Contraindication to beta-andrenoceptor antagonist or brimonidine therapy
Locations and Contacts
Artesia, California, United States
Additional Information
Starting date: July 1999
Last updated: May 27, 2011
|
